Related Experiment Video
Updated: May 3, 2026
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.1K
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the
Michael R MacDonald1, Mark C Petrie, Fumi Varyani
1Glasgow Royal Infirmary, Glasgow, UK.
European Heart Journal
|April 17, 2008
Summary
Diabetes increases cardiovascular risks in heart failure (HF) patients. This risk is significantly higher for those with preserved ejection fraction (EF) heart failure compared to low EF heart failure.
Area of Science:
- Cardiology
- Endocrinology
- Clinical Research
Background:
- Diabetes is a common comorbidity in heart failure (HF) patients.
- The impact of diabetes on cardiovascular outcomes may vary based on left ventricular ejection fraction (EF).
Purpose of the Study:
- To investigate if the risk of adverse cardiovascular outcomes associated with diabetes differs between patients with preserved ejection fraction (EF) heart failure and low EF heart failure.
Main Methods:
- Analysis of data from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program, involving 7599 patients with symptomatic HF and a wide range of EF.
- Comparison of diabetes prevalence and its association with cardiovascular outcomes across preserved EF (>40%) and low EF (<=40%) groups.
Main Results:
- Diabetes prevalence was similar in both preserved EF (28.3%) and low EF (28.5%) groups.
- Diabetes was associated with a significantly greater relative risk of CV death or HF hospitalization in preserved EF HF (HR 2.0) compared to low EF HF (HR 1.60; P = 0.0009 for interaction).
- Diabetes was an independent predictor of all-cause mortality in both EF groups, with similar risk.
Conclusions:
- Diabetes is an independent predictor of cardiovascular morbidity and mortality in heart failure patients, irrespective of ejection fraction.
- The relative risk of cardiovascular death or HF hospitalization due to diabetes is substantially higher in patients with preserved EF heart failure than in those with low EF heart failure.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
01:22Heart Failure Drugs: β-Blockers
2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
01:30Heart Failure IV: Classification and Diagnostic Evaluation
1.0K
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
1.0K
01:30Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
01:30Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790